Ian Karp | executive |
John Leonard | executive |
David Lebwohl | executive |
Laura Sepp-Lorenzino | executive |
Glenn Goddard | executive |
Maurice Raycroft | analyst |
Lisa Walter | analyst |
Greg Harrison | analyst |
Harshita Polishetty | analyst |
Troy Lankford | analyst |
Konstantinos Biliouris | analyst |
Benazir | analyst |
Maddie | analyst |
Brian Cheng | analyst |
Lydia | analyst |
Ray | analyst |
William Pickering | analyst |
Rick Bienkowski | analyst |
Yanan Zhu | analyst |
Timor Revance | analyst |
Jay Olson | analyst |
Silvan Tuerkcan | analyst |
David Lebowitz | analyst |
Jack Allen | analyst |
Good morning, and welcome to the Intellia Therapeutics Fourth Quarter and Full Year 2023 Financial Results Conference Call. My name is Drew, and I will be your conference operator today.
Following formal remarks, we will open the call up for a question-and-answer session. This conference is being recorded at the company's request and will be available on the company's website following the end of the call. [Operator Instructions].